Roland Diggelmann resigns as CEO of Roche Diagnostics after 10 years

By Sophie Chapman
The Chief Executive Officer of the Swizerland-based drugmaker, Roche Diagnostics, has announced his resignation. Ronald Diggelmann will leave the compa...

The Chief Executive Officer of the Swizerland-based drugmaker, Roche Diagnostics, has announced his resignation.

Ronald Diggelmann will leave the company next month following working for the firm for a decade.

The CEO, 51, joined Roche Diagnostics’ parent company, Roche, in 2008. Digglemann has worked for the diagnostics unit since 2012.

Prior to his role as CEO, Diggelmann was appoint as the Region Head of Asia Pacific for Roche Diagnostics.

Michael Heuer, the firm’s Region Head of Europe, Middle East, Africa, and Latin America, will be appoint the interim CEO in September.

SEE ALSO:

“I am grateful to Roland Diggelmann for his many valuable contributions during his 10 years at Roche and I wish him all the best for the future,” stated Severin Schwan, CEO of Roche.

“I am pleased to appoint Michael Heuer as interim CEO of our Diagnostics Division.”

“Michael is a very respected leader with a wealth of experience in diagnostics.”

Heuer has worked in sales, marketing, and product develop positions in Europe and the US.

The soon-to-be CEO has also held the position of Head of Roche Near Patient Testing Business Area.

Share

Featured Articles

Philip Morris International (PMI) in agreement with KT&G

PMI and KT&G are building a smoke-free world. In a new agreement between the two companies, smoke-free alternatives are within reach for smokers

Health tech leader Philips shares sustainability ambition

Roy Jakobs, Royal Philips CEO, says the health technology company’s sustainability impact plan will ‘enhance accountability & strengthen talent’

Automating gene therapy & pharma discovery at Automata

Sonia Jassi, Drug Discovery & Synthetic Biology Lead at Automata, explains how automation increases efficiency in gene therapy laboratories

Itai Hayut, CEO of Scopio Labs, on AI & blood cancer

Technology & AI

2023 predictions with Harshit Jain, global CEO of Doceree

Telehealth & COVID-19

Wolters Kluwer Health: health equity and telehealth

Telehealth & COVID-19